ITK and mature T-cell and NK-cell non-Hodgkin lymphoma: Treatment with ibrutinib or knockdown of ITK by siRNA results in reduced ITK phosphorylation and decreased activation of downstream MEK1/2 and AKT, leading to compromised survival and cytokine production as well as migration of PTCL cells (66).